Sarju Vasani

Dr. Sarju Vasani


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2020 in Cells
Verified
Journal Article
Open access
PDF file
CWChameera Ekanayake Weeramange
Chameera Ekanayake Weeramange
KTKai Dun Tang
Kai Dun Tang
SVSarju Vasani
Sarju Vasani
JLJulian Langton-Lockton
Julian Langton-Lockton
LKLiz Kenny
Liz Kenny
Chamindie K. PunyadeeraChamindie K. Punyadeera
Chamindie K. Punyadeera
Disruption of DNA methylation patterns is one of the hallmarks of cancer. Similar to other cancer types, human papillomavirus (HPV)-driven head and neck cancer (HNC) also reveals alterations in its methylation profile. The intrinsic ability of HPV oncoproteins E6 and E7 to interfere with DNA methyltransferase activity contributes to these methylation changes. There are many genes that have been reported to be differentially methylated in HPV-driven HNC. Some of these genes are involved in major cellular pathways, indicating that DNA methylation, at least in certain instances, may contribute to the development and progression of HPV-driven HNC. Furthermore, the HPV genome itself becomes a target of the cellular DNA methylation machinery. Some of these methylation changes appearing in the viral long control region (LCR) may contribute to uncontrolled oncoprotein expression, leading to carcinogenesis. Consistent with these observations, demethylation therapy appears to have significant effects on HPV-driven HNC. This review article comprehensively summarizes DNA methylation changes and their diagnostic and therapeutic indications in HPV-driven HNC.

12 August 2022 in WIREs RNA
Verified
Journal Article
Open access
JBJaikrishna Balakittnen
Jaikrishna Balakittnen
CWChameera Ekanayake Weeramange
Chameera Ekanayake Weeramange
DWDaniel Wallace
Daniel Wallace
Pascal DuijfPascal Duijf
Pascal Duijf
ACAlexandre S. Cristino
Alexandre S. Cristino
Chamindie K. PunyadeeraChamindie K. Punyadeera
Chamindie K. Punyadeera
Oral cancer (OC) is the most prevalent subtype of cancer arising in the head and neck region. OC risk is mainly attributed to behavioral risk factors such as exposure to tobacco and excessive alcohol consumption, and a lesser extent to viral infections such as human papillomaviruses and Epstein–Barr viruses. In addition to these acquired risk factors, heritable genetic factors have shown to be associated with OC risk. Despite the high incidence, biomarkers for OC diagnosis are lacking and consequently, patients are often diagnosed in advanced stages. This delay in diagnosis is reflected by poor overall outcomes of OC patients, where 5‐year overall survival is around 50%. Among the biomarkers proposed for cancer detection, noncoding RNA (ncRNA) can be considered as one of the most promising categories of biomarkers due to their role in virtually all cellular processes. Similar to other cancer types, changes in expressions of ncRNAs have been reported in OC and a number of ncRNAs have diagnostic, prognostic, and therapeutic potential. Moreover, some ncRNAs are capable of regulating gene expression by various mechanisms. Therefore, elucidating the current literature on the four main types of ncRNAs namely, microRNA, lncRNA, snoRNA, piwi‐RNA, and circular RNA in the context of OC pathogenesis is timely and would enable further improvements and innovations in diagnosis, prognosis, and treatment of OC.This article is categorized under: RNA in Disease and Development > RNA in Disease RNA in Disease and Development > RNA in Development

4 August 2020 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
JCJennifer Chen
Jennifer Chen
SVSarju Vasani
Sarju Vasani

23 March 2018 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
PDF file
SVSarju Vasani
Sarju Vasani
DYDaniel Youssef
Daniel Youssef
CLCharles Lin
Charles Lin
AWAnnabelle Wellham
Annabelle Wellham
RHRobert Hodge
Robert Hodge
Objectives: Salvage total laryngectomies (STL) are not a homogeneous group. Most will fall into two groups: i) Patients with previous AJCC stage I/II larynx cancer who have had radiotherapy to the larynx only (STL‐LOR), or ii) Patients who have had previous AJCC stage III/IV larynx cancer and subsequent radiotherapy to the larynx and draining nodal basins with concurrent cisplatin chemotherapy (STL‐CRT). We aimed to compare PCF rates following STL in these two groups.Methods: A retrospective review of the department's cohort between January 2010 and August 2015 was conducted.Results: Seventy‐seven patients underwent total laryngectomy for larynx cancer between January 2010 and August 2015. There were 10 post‐laryngectomy fistulas (13.0%). Three of these occurred in the 38 patients undergoing primary total laryngectomy (PTL), and seven in the 39 patients undergoing STL, rates of 7.9% and 17.9%, respectively. Twenty‐two patients had received radiation to the larynx alone without chemotherapy (STL‐LOR) for initial Stage I/II disease. Eleven patients had received laryngeal and neck irradiation plus cisplatin chemotherapy (STL‐CRT) for initial stage III/IV disease. Of the 22 STL‐LOR patients, two developed PCF (9.1%). Of the 11 STL‐CRT patients, five developed PCF. There was no difference in the rate of PCF between PTL and STL‐LOR. There was a statistically significant increase in PCF in STL‐CRT versus PTL (p = .009) and in PCF in STL‐CRT versus STL‐LOR (p = .027).Conclusion: Salvage laryngectomies are often treated as a homogenous group. We demonstrate that PCF rates vary significantly depending on preoperative radiation fields and the use of chemotherapy.Level of Evidence: 2b.

4 May 2026 in The Journal of the American Dental Association
Verified
Journal Article
Open access
XHXiaomin Huang
Xiaomin Huang
JBJaikrishna Balakittnen
Jaikrishna Balakittnen
CWChameera Ekanayake Weeramange
Chameera Ekanayake Weeramange
SVSarju Vasani
Sarju Vasani
AWAkila Wijesekera
Akila Wijesekera
Chamindie K. PunyadeeraChamindie K. Punyadeera
Chamindie K. Punyadeera
The incidence of oropharyngeal squamous cell carcinoma (OPSCC) is increasing, and human papillomavirus (HPV)-associated OPSCC is contributing substantially to this trend. Salivary HPV testing enables early detection of HPV-driven OPSCC. The GeneXpert system (Cepheid) is an automated polymerase chain reaction (PCR)-based diagnostic platform designed primarily for cervical cancer screening using vaginal swabs. Our goal was to adapt this platform for HPV testing using salivary oral rinse (SOR) samples to enable early detection of HPV-driven OPSCC. Patients suspected of having any type of head and neck cancers and people at higher risk of acquiring HPV infections were recruited (n = 67). A volume of 5 to 10 mL of SOR samples was tested using the GeneXpert system. Genomic DNA was extracted from the same SOR samples and analyzed using quantitative real-time PCR for human papillomavirus type 16 (HPV-16). The detection status of HPV-16 was used to evaluate the efficiency of HPV detection using the GeneXpert system. The GeneXpert system had excellent specificity of 100% and sensitivity of 72.09%. There was strong agreement with quantitative real-time PCR results (κ = .649). This confirms the suitability of SOR as a sample medium on the GeneXpert system to detect oral HPV with minimal bias. The GeneXpert system can effectively detect HPV in SOR samples. It offers rapid HPV detection, helps identify people at high risk of developing HPV-associated OPSCC, thereby holding promise for the early detection of HPV-driven OPSCC. The results of this study showed the feasibility of using SOR samples on the GeneXpert platform as a scalable, noninvasive screening approach for the early detection of patients at higher risk of developing HPV-associated OPSCC.

28 July 2026 in The Journal of the American Dental Association
Verified
Journal Article
Closed access
Chamindie K. PunyadeeraChamindie K. Punyadeera
Chamindie K. Punyadeera
XHXiaomin Huang
Xiaomin Huang
JBJaikrishna Balakittnen
Jaikrishna Balakittnen
CWChameera Ekanayake Weeramange
Chameera Ekanayake Weeramange
SVSarju Vasani
Sarju Vasani
BHBrett G.M. Hughes
Brett G.M. Hughes